Oncotarget – a medical journal against cancer
Oncotarget is a peer-reviewed open access medical journal written in English that comes out once a week. The medical journal covers the recently conducted research in the medical field of oncology. It was first published in 2010 and is being issued by the publisher Impact Journals. There are two editors in chief – Professor Mikhail Blagosklonny and Doctor Andrei V. Gudkov. The medical journal was established in order to make the results of scientific research widely available to the public and to medical professionals as well. Learn more about Oncotarget journal at Bioxbio.com.
Professor Mikhail Blagosklonny is a Russian scientist who does research in the fields of oncology and the process of aging. He is based in New York City and is a part of the Roswell Park Cancer Institute, also in New York, where he teaches oncology. Professor Mikhail Blagosklonny graduated from First Pavlov State Medical University of St. Peterburg with honors and with an M. D. in internal medicine as well as with a Ph. D. in cardiology and experimental medicine. He is also an associate editor for two other medical journals – Aging and Cell Cycle. Professor Mikhail Blagosklonny mostly researches targeted cancer therapies, the mechanisms of the aging process, various drugs for life extension, and ways to protect cells from the damage of cancer. The main mission of Oncotarget is to help in the fight against cancer and to spread further awareness of the disease.
Doctor Andrei V. Gudkov is also a part of the Roswell Park Cancer Institute as a Chair of the Department of Cell Stress Biology. He is also Senior Vice President of Basic Science. Doctor Andrei V. Gudkov attended the Cancer Research Center, USSR from which he graduated with a PH. D. in experimental oncology. He also studied at the Moscow State University, USSR and earned a D.Sci (Doctorate of Science) in molecular biology. Doctor Andrei V. Gudkov has written and co-written more than 135 articles on various scientific and medical thematic. He currently holds over twenty patents. He mostly conducts his research in the areas of gene discovery, various drug discovery approaches and in molecular targets for the treatment of cancer. Oncotarget is also available on Dove Press.